To view a list of available clinical trials, select a type of cancer below. You will get a general overview of the trial, the trial number, and a link to clinicaltrials.gov for the most complete information.
The OHC Clinical Trials program has 27 clinical research team members who are engaged in the passionate search for innovative treatments. OHC trials are offered at five of our offices right here in the Greater Cincinnati area. This easy access to national trials offers our patients early access to the latest in leading edge treatments without having to leave the Cincinnati community.
Advanced/Metastatic or Inoperable Cholangiocarcinoma - QBGJ398-301
A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF
Learn MoreBladder (urothelial) Cancer - INCB 54828-201
(OPEN AT AND, STAR AT ALL OTHER SITES) A Phase 2 STAR Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations
Learn MoreUrothelial Cancer - 42756493BLC0002
D. Waterhouse, MD. Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002).
Learn MoreUrothelial Cancer - SGN22E-001
ONLY COHORTS OPEN ARE FGFR3, MUTATIONS, OR FUSIONS. Phase II. STAR Therapeutic. Enfortumab vedotin provided. A single-arm, open-label, multicenter study of Enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy.
Learn MoreUrothelial Cancer - BLC3001
(42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)
Learn MoreHodgkin's Lymphoma - SGN35-015
a Phase II. STAR Therapeutic. Brentuximab Vedotin provided. A Phase 2 Open-Label Study of Brentuximab Vedotin in Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults age 60 and Above
Learn MoreChronic Graft versus Host Disease (GVHD) - INCB 39110-309
J. Essell. A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (GRAVITAS-309). Pt 1 Cohort is Closed
Learn MoreAcute Myeloid Leukemia - NCT03941964
(KWD only) E. Broun, M.D. A Phase 3b, Single-Arm, Multicenter Open-Label Study of sponsor provided Venetoclax in Combination with Azacitidine (SOC) or Decitabine (SOC) in an Outpatient Setting in AML Patients Ineligible for Intensive Chemotherapy.
Learn MoreMultiple Myeloma - INCB 01158-206
E. Faber, MD. A Randomized Open-Label Phase 1/2 Study of INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Participants With Relapsed or Refractory Multiple Myeloma.
Learn MoreAcute Myeloid Leukemia - BMT-CTN-1506
(KWD ONLY). J. Essell. Phase III. Therapeutic. Gilteritinib provided. A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML.
Learn MoreChronic Lymphocytic Leukemia (CLL) - M16-788
M. Islas-Ohlmayer. Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy.
Learn MoreChronic Myeoloid Leukemia (CML) - CA180653
J. Essell. Observational. No drug provided. Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-line Therapy in the United States.
Learn MoreRefractory Acute Leukemias - PTC299-HEM-001-LEU
Phase IB Study of PTC299 in Relapsed/Refractory Acute Leukemias
Learn MoreLymphoma (Non-Hodgkin's) - PCYC-1141-CA
M. Islas OIhlmayer. A Multicenter, Randomized, Double-Blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma
Learn MoreLymphoma (Non-Hodgkin's) - INCB 50465-205
M. Islas-Ohlmayer. Phase II. INCB50465 provided. A Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated with or Without a BTK Inhibitor (CITADEL-205).
Learn MoreMyeloproliferative Neoplasm (MPN) - INCB 39110-209
Phase II STAR Therapeutic. Ibrutinib/Placebo provided. An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis.
Learn MoreAdvanced Hematologic Malignancies - INCB 53914-101
A Phase 1/2 Study of INCB053914 in Subjects with Advanced Malignancies.J. Essell. Phase I/II. Therapeutic. INCB 53914 provided. A Phase 1/2 Study of INCB053914 in Subjects with Advanced Malignancies ONLY COHORT OPEN IS MF DOSE EXPANSION
Learn MoreB-Cell Non Hodgkin's Lymphoma - 17006
J. Essell, MD. A Phase 2 study of JCAR017 as Second-Line Therapy in Adult Patients with Aggressive B-cell NHL (Car-T)
Learn MoreB-Cell Non Hodgkin's Lymphoma - 17007
J. Essell, MD. A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (017007).
Learn MoreLymphoma (Hodgkins) - CA209-655
M. Islas Ohlmayer. Hodgkins Lymphoma Molecular Profiling and Clinical Outcome in U.S. Community Oncology Practices
Learn MoreMultiple Myeloma - GO41036
A PHASE Ia/Ib OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND PHARMACOKINETICS OF TIRAGOLUMAB AS A SINGLE AGENT AND IN COMBINATION WITH DARATUMUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA, AND AS A SINGLE AGENT AND IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA.(GO41036)
Learn MoreBreast Cancer - 14059
Phase I/II trial of Ibrutinib plus Trastuzumab in HER2-amplified Metastatic Breast Cancer - USOR 14059
Learn MoreBreast Cancer - FLEX Registry
MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)
Learn MoreColorectal & Ovarian - MK3475-770
P. Ward. A ph. I/II study of Galinpepimut-S in combination with Pembrolizumab (MK-3475) in patients with selected advanced cancers
Learn MoreLung Cancer - MRTX-500
(Sitravatinib arm only). D. Waterhouse. Phase II. Therapeutic. Sitravatinib provided. A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination with Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer (MRTX-500).
Learn MoreLung Cancer - 2002
STAR Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non–Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)
Learn MoreLung Cancer - MK3475-789
A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)
Learn MoreLung Cancer - Brigatinib-3001
A Phase 3 STAR Randomized Open-label Study of Brigatinib (ALUNBRIG™) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)
Learn MoreLung Cancer - BLU-667-1101
(BAM only) A Phase 1 STAR Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (BLU-667-1101) RET Mutation or Rearrangement.
Learn MoreNon Small Cell Lung Cancer - Mirati 516-005
A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy
Learn MoreNon Small Cell Lung Cancer - D9103C00001
D9103C00001: A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515)
Learn MoreMetastatic Castration-resistant Prostate Cancer - CO-338-052
Phase II. STAR Therapeutic. Rucaparib provided. A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency (TRITON2).
Learn MoreMetastatic Castration-resistant Prostate Cancer - CO-338 063
Phase III. STAR Therapeutic. Atezolizumab provided. A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician’s Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency (TRITON3).
Learn MoreMetastatic Castration-resistant Prostate Cancer - i3Y-MC-JPCM
A Phase II STAR Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer
Learn MoreFGFR mutated solid tumor - INCB 54828-207
(INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
Learn MoreBreast, lung, Non-Hodgkin's Lymphoma, prostate - 2017-0758
P. Ward. Observational. A Prospective Observational Study Comparing the Effectiveness of Neulasta® (pegfilgrastim) Onpro® kit to Other Physician Choice Options for Prophylaxis of Febrile Neutropenia in Subjects with Non-Myeloid Malignancies at High Risk for Febrile Neutropenia (breast cancer, lung cancer, NHL or prostate cancer starting myelosuppressive chemotherapy in the neoadjuvant/adjuvant or first line advanced/metastatic setting with at least 4 anticipated chemotherapy cycles- no dose dense).
Learn More